Drugs / Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06949267 | Jun 2025 → Sep 2026 expected | acute graft versus host disease | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells | “A Prospective, Randomized Controlled Study of Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells (iMSC) for the Prevention of Acute Graft-versus-host Disease...” NCT06949267 ↗ |
| Known as | iMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06949267 ↗ |
| Modality | Cell therapy | “Human Induced Pluripotent Stem Cell-derived Mesenchymal Stromal Cells (iMSC)” NCT06949267 ↗ |
| Route | Other | “iMSC injection” NCT06949267 ↗ |